Our lead TCR-T therapy candidate, TSC-101, is in development for the treatment of patients with hematologic malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) (the ALLOHA™ trial, NCT05473910). TSC-101 is administered after allogeneic bone marrow transplantation (hematopoietic cell transplantation or HCT) and has been designed to treat residual disease and therefore prevent relapse post-HCT. The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors and has developed its ImmunoBank to provide customized multiplex TCR-Ts for patients with a variety of cancers (the PLEXI-T™ solid tumor trial, NCT05973487).

TScan was founded in early 2018 to discover and develop transformational TCR-Ts using a novel T cell target discovery platform. The Company began based on the premise that we can learn from patients who are winning their fight against cancer to treat those who are not. Over the years, we have used this technology to understand how T cells naturally recognize and fight cancer and have leveraged this information to build a broad pipeline of TCR-T therapy candidates. TScan’s core technology is extremely versatile and is applicable across multiple therapeutic areas, including cancer, autoimmunity, and infectious diseases.

Meet our expert management team.